Glioblastoma multiforme (GBM) has the highest rate of vascular proliferation among
solid tumors. Angiogenesis is the central feature of rapid tumor growth in GBM and
therefore remains an appealing therapeutic target in the treatment of these highly
malignant tumors. Antiangiogenic therapy is emerging as an important adjuvant treatment.
Multiple antiangiogenic agents targeting various sites in vascular endothelial growth
factor (VEGF) and integrin pathways have been tested in clinical trials of newly diagnosed
and recurrent GBMs. These include bevacizumab, enzastaurin, aflibercept, cediranib,
and cilengitide. In this review, we discuss the current status and challenges facing
clinical application of antiangiogenic treatment including anti-VEGF therapy and integrin
pathway agents' therapy in glioblastoma. Here, we highlight a strong biologic rationale
for this strategy, also focusing on integrin pathways. PubMed-indexed clinical trials
published in English on antiangiogenic treatment of glioblastomas in the past 5 years
were reviewed. The results of the current clinical trials of these agents are presented.
Key-words:
Antiangiogenic therapy - cilengitide - glioblastoma multiforme - integrin - vascular
endothelial growth factor
